ReViral

ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered RSV fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a paediatric patient population and the other in an adult stem-cell transplant patient population. The company also has an N-protein replication inhibitor program in preclinical development.